OnePoint Patient Care’s Post

Prescribing generic specialty medications for #MultipleSclerosis (MS) presents challenges, notably in ensuring medication quality and efficacy. A significant concern is the variability in the quality of #generic medications, as highlighted by the International Journal of MS Care. They reported a case where a patient experienced a severe exacerbation after being switched to a generic version of #teriflunomide, which was found to be substandard. This underscores the importance of careful consideration and monitoring when prescribing generics to ensure patient safety and treatment effectiveness. How can we as #pharmacists and MS specialists contribute to patients safety and medication effectiveness ⁉️ #patientsafety #TheMSPharmacist #specialtypharmacy

This study helps to highlight why LTC@Home is so important. That initial CMR and CMRs after each medication change can stop these interactions BEFORE they hospitalize patients. Long Term Care at Home Pharmacy Network

High-Alert Medication List for Acute Care Settings Updated for 2024 🏥💊 High-alert medications are a critical aspect of drug therapy, but errors involving them can have severe and even fatal consequences. In 2024, the Institute for Safe Medication Practices (ISMP) has updated their list, drawing insights from practitioner feedback, clinical literature, and expert input. Notable changes include the addition of tranexamic acid, due to its neurotoxic properties when administered via the wrong route. Reducing errors with these medications requires safeguards such as limited access, clinical decision support, standardized procedures, double checks, and improved information access. Check out the updated list and make sure your organization is taking necessary precautions to ensure patient safety. 💪 https://lnkd.in/d_HsZBmN #PatientSafety #MedicationSafety #HealthcareUpdates #ISMP #HighAlertMedications

🚨 Urgent Healthcare Update 🩺: The UK faces persistent drug shortages, impacting patients, notably those with #type2diabetes, on #glp1 RAs. NHS England's recent Patient Safety Alert highlights the severity, with supplies unlikely to stabilize until mid-2024. Global shortages, driven by off-label #semaglutide use for weight loss, prompted Diabetes UK to advocate for responsible prescription practices. Notably, #Ozempic, #Rybelsus, #Trulicity, and others are in short supply, leading #novonordisk to collaborate with #mhra to address the increased demand. The challenge intensifies as diabetes medications like Ozempic gain popularity for unintended uses, hindering access for patients in need. Beyond diabetes, shortages extend to ADHD medications and hormone therapies, compounding the strain on healthcare systems. Let's raise awareness, support responsible prescribing, and collaborate to find sustainable solutions for these critical medication shortages. 🌐💙 Read more: https://lnkd.in/guR5gWMr #pharmaceuticaltechnology #globaldata #HealthcareChallenge #DrugShortages #PatientCare #GlobalHealthcare

Interesting to see #subcutaenous #ocrevus making progress towards market entry. With an #EMA decision in the near future, could the #US be far behind? Also, once it is approved, what will happen to #Kesimpta, #Briumvi, and even IV Ocrevus? IV Ocrevus is already approved for home infusion, so 10 minutes (q6months) in a patient's home for the SQ version could really raise the profile (with #multiplesclerosis #patients) for an already successful therapy. https://lnkd.in/eJ7qH3ZS

Addressing the Challenge of Adverse Drug Reactions in Elderly with Hidden Kidney Issues Tackle adverse drug reactions in the elderly with hidden kidney issues. Our guide addresses challenges, offering solutions for safer and personalized medication management. Learn More: https://lnkd.in/gRGSWVB3

In the last weeks of 2023, the FDA approved the first test to identify risk of developing opioid use disorder (OUD). 'AvertD is intended to be used before the first use of oral opioid painkillers in those who are being considered for a 4 to 30 days prescription for the treatment of acute pain, such as in patients scheduled to undergo a planned surgical procedure.' Want to know more? https://loom.ly/pxfKPi4 #substanceusedisorder #opioidpainkiller #opioiduse #oud #prevention #opioidusedisorder

A meta-analysis and real-world evidence-based assessments were conducted to investigate the adverse events associated with anti-IL-5 drugs in patients diagnosed with #eosinophilic #asthma. The findings of this study shed light on the potential risks and side effects of these medications. The results provide valuable insights for healthcare professionals and patients alike, enabling them to make informed decisions regarding the use of anti-IL-5 drugs. It is essential to weigh the benefits against the potential adverse effects when considering the treatment options for eosinophilic asthma. #AsthmaResearch #DrugSafety https://buff.ly/49oXGKe

CDC is updating its Expanded Access-Investigational New Drug (EA-IND) protocol to clarify eligibility for TPOXX, the antiviral drug used to treat mpox. This update ensures that people who might most benefit from TPOXX will still get treatment either through CDC or the STOMP trial, which will help us understand how effective TPOXX is in treating mpox and which patients might benefit from this drug. Learn more: https://bit.ly/4abPM6R